Latest news with #OGN
Yahoo
a day ago
- Business
- Yahoo
Organon (OGN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest close session, Organon (OGN) was down 1.87% at $9.46. This change lagged the S&P 500's 0.01% loss on the day. Meanwhile, the Dow lost 0.32%, and the Nasdaq, a tech-heavy index, added 0.05%. Heading into today, shares of the pharmaceutical company had lost 2.43% over the past month, lagging the Medical sector's loss of 1.59% and the S&P 500's gain of 5.37%. The upcoming earnings release of Organon will be of great interest to investors. The company is forecasted to report an EPS of $0.94, showcasing a 16.07% downward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $1.55 billion, indicating a 3.35% decline compared to the corresponding quarter of the prior year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.83 per share and a revenue of $6.24 billion, indicating changes of -6.81% and -2.48%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for Organon. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.55% higher. Organon is currently a Zacks Rank #2 (Buy). With respect to valuation, Organon is currently being traded at a Forward P/E ratio of 2.52. For comparison, its industry has an average Forward P/E of 15.4, which means Organon is trading at a discount to the group. It is also worth noting that OGN currently has a PEG ratio of 0.96. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. OGN's industry had an average PEG ratio of 1.52 as of yesterday's close. The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 90, placing it within the top 37% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Organon & Co. (OGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
a day ago
- Business
- Business Wire
ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until to file lead plaintiff applications in securities class action lawsuits against Organon & Co. (NYSE: OGN), if they purchased the Company's securities between November 3, 2022 and April 30, 2025, inclusive (the 'Class Period'). These actions are pending in the United States District Court for the District of New Jersey. What You May Do If you purchased securities of Organon and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( or visit to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by July 22, 2025. About the Lawsuits Organon and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On March 10, 2025, pre-market, the Company announced its financial results for the first quarter of 2025, disclosing, among other things, that management had reset the Company's dividend payout, from $0.28 to $0.02, contradicting its prior statements assuring investors that the regular quarterly dividend was a number one priority and that the Company was committed to its capital allocation strategy through the aforementioned dividend. On this news, the price of Organon's shares fell more than 27%, from a closing market price of $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. The first-filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322. A subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanded the class period. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
Yahoo
10-07-2025
- Business
- Yahoo
Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program
Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational candidate OG-6219 in endometriosis-related pain, with OG-6219 being an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor. A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. (NYSE:OGN) acquired OG-6219 through its 2021 acquisition of Forendo Pharma. The compound did not exhibit improvement in moderate-to-severe endometriosis-related overall pelvic pain in the study as compared to the placebo, which is why Organon & Co. (NYSE:OGN) plans to discontinue the clinical development program. Juan Camilo Arjona Ferreira, M.D., Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), stated that while the study results were disappointing, the company remains committed to its focus on improving the lives of women with endometriosis. Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women's health, established brands, and biosimilars. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
10-07-2025
- Business
- Yahoo
Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program
Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational candidate OG-6219 in endometriosis-related pain, with OG-6219 being an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor. A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. (NYSE:OGN) acquired OG-6219 through its 2021 acquisition of Forendo Pharma. The compound did not exhibit improvement in moderate-to-severe endometriosis-related overall pelvic pain in the study as compared to the placebo, which is why Organon & Co. (NYSE:OGN) plans to discontinue the clinical development program. Juan Camilo Arjona Ferreira, M.D., Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), stated that while the study results were disappointing, the company remains committed to its focus on improving the lives of women with endometriosis. Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women's health, established brands, and biosimilars. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
07-07-2025
- Business
- Business Wire
Altius Provides 2 nd Quarter 2025 Project Generation Update
ST. JOHN'S, Newfoundland and Labrador--(BUSINESS WIRE)-- Altius Minerals Corporation (ALS:TSX) (ATUSF: OTCQX) ('Altius') is pleased to update its Project Generation ('PG') business activities and its public junior equities portfolio. The market value of equities in the portfolio at June 30, 2025 was $87.3 million, compared to $71.4 million at March 31, 2025. In addition, net cash proceeds of $293,000 were generated from modest portfolio sales. An updated list of the public equity holdings has been posted to the Altius website at Portfolio Highlights Overall performance of the portfolio during the quarter was largely driven by its holding of 39,557,961 common shares or an approximate 19.6% interest in Orogen Royalties Inc. (TSX-V:OGN) ('Orogen'), which announced a plan of arrangement with Triple Flag Precious Metals Corp. ('Triple Flag') on April 22 nd, 2025 effectively resulting in Triple Flag's acquisition of Orogen's 1.0% NSR royalty on the Expanded Silicon project. Altius subsequently reported its support of the agreement and at Orogen's Annual General and Special Meeting on June 27, 2025 shareholders overwhelmingly approved the Plan of Arrangement. Triple Flag is acquiring all the issued and outstanding common shares of Orogen for total consideration of approximately $421 million, or $2 per share. In exchange for Orogen shares, Altius will receive cash, Triple Flag shares, and 9,889,490 shares (16.7%) of a spin out company ('Orogen SpinCo') that will hold all of Orogen's exploration assets, early-stage royalties, and the producing Ermitaño royalty. Total implied gross proceeds to Altius are expected to be in the range of $80 million, with some variability depending on the final allocation of cash and shares and the value of Orogen SpinCo. This compares to an original cost base of under $15 million. Altius also renewed its exploration alliance with Orogen (henceforth Orogen SpinCo) for the fourth consecutive year, whereby both parties will continue to conduct early-stage mineral exploration work in Nevada. Altius also directly holds a separate 1.5% NSR royalty covering the Expanded Silicon project for which it is currently considering strategic alternatives. AbraSilver Resource Corp. (TSX: ABRA; OTCQX: ABBRF) ('Abra') announced a potential new porphyry copper discovery at the La Coipita project in the San Juan Province of Argentina. Hole DDH-LC25-006 was highlighted by 621 metres ('m') grading 0.38% Cu, 0.07 g/t Au and 62 ppm Mo, from 410 m to 1,031 m, which included 114 m grading 0.70% Cu, 0.07 g/t Au and 81 ppm Mo, from 410 m to 524 m down-hole depth, interpreted as a secondary enrichment zone. The project lies within the Miocene porphyry-epithermal belt of Argentina and Chile which hosts significant porphyry Cu-Mo-Au mineral deposits such as Filo del Sol to the north and Los Azules, Los Pelambres, and El Pachón to the south. The project is being advanced by a subsidiary of Teck Resources Limited under the terms of an earn-in and joint venture agreement between it and Abra. Altius holds a royalty acquisition right to acquire a 1.10% net smelter return royalty covering the project as part of a strategic equity investment in Abra in 2020 when it entered into the option agreement to acquire a 100% interest in the La Coipita project. As per the terms of the Option Agreement, the Vendor retained a 1.10% royalty and of Abra assigned to Altius an exclusive right to purchase the royalty for US$5,000,000 at any time up to the commencement of construction on the project. In late June Altius sold its Roebucks base metals project in central Newfoundland to a private company, VMS Mining Inc. ('VMS'), for 10 million common shares while also retaining a 2.5% NSR royalty covering the project. Canstar Resources Inc. (TSX-V:ROX) ('Canstar') also announced the execution of a letter of intent (LOI) with VMS establishing terms for an $11.5-million exploration joint venture exploring the company's polymetallic volcanogenic massive sulphide assets in Newfoundland. Altius retains a 2% NSR royalty over certain mineral licenses in the Buchans/Mary March area being explored by Canstar. Altius also owns 11,855,524 (~8%) common shares of Canstar and a 2% NSR royalty covering its Golden Baie precious metals project in Newfoundland. Altius is also presently active in evaluating and negotiating potential exploration alliances and/or investment opportunities that support royalty creation in multiple current and new jurisdictions. Qualified Person Lawrence Winter, Ph.D., Vice President, Generative and Technical for Altius, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, is responsible for the scientific and technical data presented herein and has reviewed, prepared and approved this release. About Altius Altius's strategy is to create per share growth through a diversified portfolio of royalty assets that relate to long life, high margin operations. This strategy further provides shareholders with exposures that are well aligned with sustainability-related global growth trends including the electricity generation transition from fossil fuel to renewables, transportation electrification, reduced emissions from steelmaking and increasing agricultural yield requirements. These macro-trends each hold the potential to cause increased demand for many of Altius's commodity exposures including copper, renewable based electricity, several key battery metals (lithium, nickel and cobalt), clean iron ore, and potash. In addition, Altius runs a successful Project Generation business that originates mineral projects for sale to developers in exchange for equity positions and royalties. Altius has 46,315,304 common shares issued and outstanding that are listed on Canada's Toronto Stock Exchange. It is a member of both the S&P/TSX Small Cap and S&P/TSX Global Mining Indices.
